Higher 10-year PREVENT risk scores were associated with subclinical CVD, with each unit increase in HF risk yielding a 2.67-fold higher odds of diastolic dysfunction (95% CI 2.25-3.18).
Cohort (n=1,138)
Yes
Do the AHA PREVENT 10-year risk scores associate with subclinical cardiovascular disease in an asymptomatic community population?
The AHA PREVENT risk equations strongly correlate with the presence of subclinical heart failure and coronary atherosclerosis in asymptomatic individuals without known cardiovascular disease.
Odds Ratio: 2.67 (95% CI 2.25–3.18)
BACKGROUND: The American Heart Association Predicting Risk of Cardiovascular Disease Events risk scores estimate cardiovascular disease (CVD) risk, including heart failure (HF) and atherosclerotic CVD (ASCVD) events. Whether they associate with subclinical CVD in an asymptomatic community population is unknown. METHODS: We analyzed 1138 participants from the multicenter PBHS (Project Baseline Health Study) cohort, who underwent echocardiography and coronary artery calcium scoring and were free of known CVD. Subclinical CVD was defined as the presence of subclinical HF or subclinical coronary artery disease. Subclinical HF included left ventricular diastolic dysfunction, left ventricular hypertrophy, or low ejection fraction (0. Predicting Risk of CVD Events 10-year risk score associations with subclinical CVD were assessed using logistic regression and area under the receiver operating characteristic curve analysis. RESULTS: Median age was 52 (41-64) years; 64% were White; and 57% were women. Subclinical HF was found in 182 (16%) participants, predominantly with left ventricular diastolic dysfunction (14%). Diastolic dysfunction prevalence increased from 5.8% in low-risk HF groups to 44.1% in intermediate-/high-risk HF groups. Each unit increase in 10-year HF risk corresponded to 2.67-fold higher odds of diastolic dysfunction (95% CI, 2.25-3.18; area under the curve, 0.81). Subclinical coronary artery disease was present in 466 (41%) participants, with prevalence increasing from 28.5% in low-risk ASCVD groups to 79.3% in intermediate-/high-risk ASCVD groups. Each unit increase in 10-year ASCVD risk was associated with 2.91-fold higher odds of any coronary calcification (95% CI, 2.54-3.35; area under the curve, 0.80), increasing to 4.76-fold for coronary artery calcium >100 (95% CI, 3.70-6.12; area under the curve, 0.86) and 5.60-fold for coronary artery calcium >300 (95% CI, 3.89-8.05; area under the curve, 0.87). CONCLUSIONS: In an asymptomatic CVD-free community sample, subclinical CVD was increasingly associated with higher 10-year HF and ASCVD risks calculated by the Predicting Risk of CVD Events equations.
Fahed et al. (Fri,) conducted a cohort in Asymptomatic, free of known cardiovascular disease (n=1,138). Predicting Risk of Cardiovascular Disease Events (PREVENT) risk scores vs. Low-risk groups was evaluated on Subclinical cardiovascular disease (subclinical heart failure or subclinical coronary artery disease) (OR 2.67, 95% CI 2.25-3.18). Higher 10-year PREVENT risk scores were associated with subclinical CVD, with each unit increase in HF risk yielding a 2.67-fold higher odds of diastolic dysfunction (95% CI 2.25-3.18).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: